- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02255643
Motor Threshold and Motor Cortex Stimulation
The Relationship Between Motor Threshold and Effective Stimulation Threshold During Motor Cortex Stimulation
Motor cortex stimulation (MCS) is a form of brain stimulation for patients with neuropathic pain not responsive to medication. An electrode is placed on the surface of the brain and connected to a programmable battery in the chest.
The strength of stimulation can be individually adjusted by changing the voltage of stimulation. A too high voltage will produce side effects (e.g. seizures) while a too low voltage will not provide pain control. The aim of this study is to analyze the optimal stimulation parameters in patients already implanted with a motor cortex stimulation who have received good pain relief. The actual voltage may vary widely between patients but the investigators feel that there may be an "ideal" voltage if it is measured as a percentage of motor threshold (PMT). If motor threshold is the stimulation voltage that can evoke a muscle contraction then a PMT = 80% would be a voltage that was eighty percent of that value. Although the actual voltage may be widely different between patients, the percentage needed may be very similar. The investigators therefore plan to measure the effect of different percentages of PMT in patients already being treated with motor cortex stimulation.
Systematic analysis of the findings of this study might help the individual participant and future patients to better programming and less side effects.
Study Overview
Detailed Description
Motor cortex stimulation (MCS) is a form of brain stimulation for patients with medically refractory neuropathic pain. The strength of stimulation can be individually adjusted by changing the voltage of stimulation. Too high voltage will produce side effects (e.g. seizures) while too low voltage will not provide pain control. The aim of this study is to analyze the optimal stimulation parameters in patients already implanted with a motor cortex stimulation who have received good pain relief. The actual voltage may vary widely between patients (because of the individual variations in tissue resistance) but the investigators feel that there may be an "ideal" voltage if it is measured as a percentage of motor threshold (PMT).
If motor threshold is the voltage that can evoke a muscle contraction then a PMT = 80% would be a voltage that was eighty percent of that value. Although the actual voltage may be different between patients, the effective PMT may be similar since it represents a more physiologic measure of stimulation.
Systematic analysis of the findings of this study might help the individual participant and future patients by reducing voltage to the lowest effective setting and reducing the chance of seizures.
Motor cortex stimulation is used in the treatment of neuropathic pain since 1991 but still no guidelines for programming exist and programming is therefore mainly bases on trial and error. This is mostly due to many variables influencing the choice of stimulation parameters and significant individual differences in susceptibility to stimulation. Routinely the motor threshold is determined during programming to identify the superior limit of voltage at which twitching is induced. No stimulation above the motor threshold should be performed as this is known to cause seizures. The voltage of simulation that will be effective for an individual is unknown at the beginning of the treatment.
The investigators try to find the lowest effective voltage because that will reduce the risk of stimulation-induced seizures and prolong the life of the pacemaker.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E3
- Vancouver General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patient more than 18 years of age
- Chronic neuropathic pain effectively treated with motor cortex stimulation
- Stable medication during the trial
- Willing and able to comply with the study protocol and to return per the follow-up visit schedule and able to provide informed consent.
Exclusion Criteria:
- Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact the perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by the investigator
- Technical malfunction of the MCS device
- History of seizures
- Unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: -10% of effective PMT
Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
|
The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
|
Active Comparator: former setting (+/- 0% of PMT)
Patients are set to their original PMT at start of study, Changes in PMT settings
|
The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
|
Experimental: +10% of effective PMT
Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
|
The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Pain measured on the Visual Analogue Scale with different PMT Settings
Time Frame: at the End of each trial period, typically 14 days after changes in PMT Settings
|
at the End of each trial period, typically 14 days after changes in PMT Settings
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of Life assessment with the SF-36 questionnaire
Time Frame: at the end of each trial period, typically at 14 days
|
at the end of each trial period, typically at 14 days
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain assessment with the McGill pain questionnaire to record impact of pain
Time Frame: at the end of each trial period, typically 14 days
|
at the end of each trial period, typically 14 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochir Suppl (Wien). 1991;52:137-9. doi: 10.1007/978-3-7091-9160-6_37.
- Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Treatment of thalamic pain by chronic motor cortex stimulation. Pacing Clin Electrophysiol. 1991 Jan;14(1):131-4. doi: 10.1111/j.1540-8159.1991.tb04058.x.
- Peyron R, Garcia-Larrea L, Deiber MP, Cinotti L, Convers P, Sindou M, Mauguiere F, Laurent B. Electrical stimulation of precentral cortical area in the treatment of central pain: electrophysiological and PET study. Pain. 1995 Sep;62(3):275-286. doi: 10.1016/0304-3959(94)00211-V.
- Lima MC, Fregni F. Motor cortex stimulation for chronic pain: systematic review and meta-analysis of the literature. Neurology. 2008 Jun 10;70(24):2329-37. doi: 10.1212/01.wnl.0000314649.38527.93.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H14-01258
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
Clinical Trials on Change of PMT setting
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Universitat de VicActive, not recruitingConstipation Chronic IdiopathicSpain
-
GCS Ramsay Santé pour l'Enseignement et la RechercheTerminated
-
University Hospital, Clermont-FerrandCompletedICU Patients | Intubation | Pulmonary Function | Tracheotomy | Spontaneously BreathingFrance
-
University Hospital, AngersMinistry of Health, FranceCompletedAcute Respiratory Distress Syndrome | Acute Lung InjuryFrance
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Completed
-
Rutgers, The State University of New JerseyCompletedType 2 DiabetesUnited States
-
National Taiwan University HospitalCompleted
-
Centre Hospitalier Universitaire de NiceMedtronicCompleted
-
Nova Southeastern UniversityNational Institute on Drug Abuse (NIDA)CompletedHIV Infection | Substance AbuseUnited States
-
Florida State UniversityNational Institute on Drug Abuse (NIDA); National Center for Advancing Translational...CompletedHIV/AIDS | Infectious Disease | Substance Use | Older Adults | Behavioral InterventionUnited States